Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

3 results about "Amisulpride" patented technology

Amisulpride, sold under the brand name Solian among others, is an antipsychotic medication used to treat schizophrenia. It is also used to treat dysthymia. It is usually classed with the atypical antipsychotics. Chemically it is a benzamide and like other benzamide antipsychotics, such as sulpiride, it is associated with a high risk of elevating blood levels of the lactation hormone, prolactin (thereby potentially causing the absence of the menstrual cycle, breast enlargement, even in males, breast milk secretion not related to breastfeeding, impaired fertility, impotence, breast pain, etc.), and a low risk, relative to the typical antipsychotics, of causing movement disorders. It has also been found to be modestly more effective in treating schizophrenia than the typical antipsychotics.

Treatment of postoperative emesis with amisulpride

PendingCN122272818APostoperative vomitingAnesthesia
Amisulpride can be used to treat (especially prevent) postoperative vomiting in patients undergoing surgery, where postoperative vomiting could be potentially dangerous.
Owner:LXO IRELAND DESIGNATED EVENT CO

Rescue treatment of postoperative nausea and vomiting

PendingCN122351229AHave NauseaPharmaceutical drug
Amisulpride can be used to treat postoperative nausea and / or vomiting in patients who have been given prophylactic medication for postoperative nausea and / or vomiting, and in which the dose of amisulpride is 7.5 to 15 mg.
Owner:LXO IRELAND DESIGNATED EVENT CO

Psychogenic agents and uses thereof

The amisulpride derivatives and R enantiomers of amisulpride disclosed herein, or pharmaceutical compositions thereof, can be used to antagonize serotonin (e.g., 5-HT2a, 5-HT7) receptors in a subject, alone or in combination with other CNS active agents. The amisulpride derivatives and R enantiomers of amisulpride or pharmaceutical compositions thereof disclosed herein can be used, alone or in combination with other CNS active agents, for the treatment of one or more conditions responsive to modulation of serotonin (e.g., 5-HT2a, 5-HT7) receptors in a subject. The amisulpride derivatives and R enantiomers of amisulpride or pharmaceutical compositions thereof disclosed herein can be used, alone or in combination with other CNS active agents, for the treatment of one or more disorders associated with abnormal serotonin levels in the brain.
Owner:LB PHARMACEUTICALS INC